STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD.

Staidson (Beijing) BioPharmaceuticals Co., Ltd.

300204

CNE100001237

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 30/05/2024 BST			5-day change	1st Jan Change
6.36 ^CNY	+1.92%		-1.40%	-37.40%

04-24	Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-25	Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Staidson BioPharmaceuticals Co., Ltd. Announces Election of Board of Directors

August 12, 2021 at 08:34 pm

Staidson (Beijing) BioPharmaceuticals Co., Ltd. at its AGM held on August 11, 2021, approved the election of Yang Lianchun as non-independent director; election of Zhao Li and Zhao Jiajun as independent directors.

Latest news about Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-24	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-25	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	25/10/23	CI
Staidson BioPharmaceuticals Co., Ltd.(XSEC:300204) added to S&P Global BMI Index	18/09/23	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/08/23	CI
Staidson BioPharmaceuticals Co., Ltd. amended terms of the transaction	25/06/23	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/04/23	CI
Staidson Pharma Unit Gets FDA's Emergency Use Authorization for COVID-19 Drug; Shares Soar 18%	06/04/23	MT
Review Into Staidson Biopharma Unit's Anti-COVID-19 Drug Shows Safety, Tolerability in Patients; Shares Jump 5%	17/02/23	MT
Staidson's Respiratory Drug Shows Safety in Trial	23/01/23	MT
Chinese Shares Finish Lower; Staidson Falls 8% After Signing R&D Deal With Germany’s InflaRx	23/12/22	MT
Staidson Forms R&D Deal With Germany’s InflaRx	23/12/22	MT
Staidson BioPharmaceuticals Co., Ltd. announced that it expects to receive CNY 580 million in funding	21/12/22	CI
Inflarx Gmbh and Staidson Biopharmaceuticals Co., Ltd Enters into Third Addendum to the Co-Development Agreement	21/12/22	CI
InflaRx N.V. announced that it expects to receive $2.5 million in funding from Staidson BioPharmaceuticals Co., Ltd.	20/12/22	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/10/22	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22/08/22	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	18/04/22	CI
Staidson BioPharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	18/04/22	CI
Chinese Shares End Lower; Pharmaceutical Stlocks Suffer Huge Losses After WuXi Biologics' US Sanction	11/02/22	MT
Staidson Beijing Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	11/10/21	CI
Staidson Beijing Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	23/08/21	CI
Staidson BioPharmaceuticals Co., Ltd. Announces Election of Board of Directors	12/08/21	CI
Staidson Beijing Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	19/04/21	CI
Staidson Beijing Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	29/10/20	CI

Chart Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Duration

Period

Chart Staidson (Beijing) BioPharmaceuticals Co., Ltd.

More charts

Company Profile

Staidson (Beijing) Biopharmaceuticals Co., Ltd. is a China-based company principally engaged in the research, development, manufacture and sales of innovative therapeutic medicine with independent intellectual property rights including protein medicine, genetic medicine and chemical medicine, among others. The Companyâs products include mouse nerve growth factor for injection, which are applied in the neuroprotection and treatment of nerve injuries, as well as polyethylene glycol electrolyte powders, which are applied in the bowel cleansing and treatment of constipation. The Company mainly distributes its products in domestic market.

Sector

Pharmaceuticals

Calendar

26/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD.	-37.40%	420M
CSL LIMITED	-2.29%	89.87B
SAMSUNG BIOLOGICS CO.,LTD.	-3.95%	37.57B
UCB	+63.05%	26.47B
BIOMARIN PHARMACEUTICAL INC.	-22.14%	14.25B
INCYTE CORPORATION	-7.96%	12.99B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.33%	11.93B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-46.33%	10.84B
SWEDISH ORPHAN BIOVITRUM AB	+5.77%	9.11B
INNOVENT BIOLOGICS, INC.	-17.66%	7.32B